Number	Group
14	Medical specialists (m/f) , psychological psychotherapists (m/f) and child and adolescent psychotherapists (m/f) who are subject to the obligation to undergo further training*
12	Number of medical specialists (m/f) from no. 1 who have completed a five-year period of further training and are therefore subject to the obligation to provide evidence
12	Number of those persons from no. 2 who have provided proof of further training according to Article 3 of the G-BA regulations

* according to the “Provisions of the Joint Federal Committee for the Further Training of Medical Specialists (m/f), Psychological Psychotherapists (m/f) and Child and Adolescent Psychotherapists (m/f) in Hospitals”

General information

Drug therapy safety

Steering committee

Drug commission

Availability of appropriate, topic-specific informational materials for patients on AMTS e.g. for chronic diseases, for high-risk drugs, for children

Electronic support for the admission and anamnesis process (e.g. import of patient master data or medication plans, use of a drug knowledge database, input screen for drugs or anamnesis information)

Possibility of electronic prescription i.e. structured entry of active substances (or name of the preparation), form, dose, dose frequency (e.g. in the HIS, in prescription software)

Provision of one or more electronic drug information systems (e.g. Lauer-Taxe®, ifap klinikCenter®, Gelbe Liste®, Fachinfo-Service®)

Electronic support for the supply of patients with drugs

Vorhandensein von elektronischen Systemen zur Entscheidungsunterstützung (z.B. Meona®, Rpdoc®, AIDKlinik®, ID Medics® bzw. ID Diacos® Pharma)
elektronisches Medikamentenbestellsystem, elektronische Patientenakte

Electronic documentation of the administration of drugs

Measures to minimise medication errors

Fallbesprechungen
Maßnahmen zur Vermeidung von Arzneimittelverwechslung
Spezielle AMTS-Visiten (z. B. pharmazeutische Visiten, antibiotic stewardship, Ernährung)
Teilnahme an einem einrichtungsübergreifenden Fehlermeldesystem (siehe Kapitel 12.2.3.2)

Measures to ensure seamless drug therapy after discharge

Aushändigung von arzneimittelbezogenen Informationen für die Weiterbehandlung und Anschlussversorgung der Patientin oder des Patienten im Rahmen eines (ggf. vorläufigen) Entlassbriefs
Aushändigung des Medikationsplans
bei Bedarf Arzneimittel-Mitgabe oder Ausstellung von Entlassrezepten

Special instrument-based equipment

Research & teaching

Job

FL04 - Project-related cooperation with colleges and universities

Explanation

Parkinson-Zentrum Universität Göttingen-Kassel, Kooperation zur Tiefen Hirnstimulation mit Universität Göttingen, ExpoBiome Projekt mit Universität Luxemburg und Charite Berlin, diverse Michael J. Fox-Projekte, Zusammenarbeit mit der Universität Göttingen

FL02 - Lectureships / teaching posts at universities of applied sciences

Explanation

Frau Prof. Dr. med. Brit Mollenhauer: Studentenkurse Universität Göttingen Frau PD Dr. med. Friederike Sixel-Döring: Studentenkurre Universität Marburg, Dr. med. Maria-Lucia Muntean Studentenkurse Göttingen

FL03 - Student training (clinical traineeship / internship year)

Explanation

FL05 - Participation in multi-centre Phase I/II studies

Explanation

5 Studien (Thema Parkinson), 1 Studie (Thema PSP), 1 Studie (Thema LBD), 1 Studie MSA, 1 Huntington Studie

FL01 - Lectureships / teaching posts at colleges and universities

Explanation

Frau UnivProf. Dr. med. Claudia Trenkwalder:W3-Stiftungsprofessur UMG, Kurs: Schlafmedizin Universität Göttingen, Frau Prof. Dr. med. Brit Mollenhauer: Stiftungsprofessur Universität Göttingen, Frau PD Dr. med. Friederike Sixel-Döring: Lehrauftrag Universität Marburg

FL07 - Initiation and management of uni-centric/multi-centric clinical/scientific studies

Explanation

Langzeitstudie"DeNoPa", (De Novo Parkinson, früher unbehandelter Parkinson), Panda-Studie, Enroll-HD-Studie (Huntington), Studie zur Kognition bei Tiefen-Hirn-Stimulation (THS) und diverse andere

FL08 - Editors of scientific journals/textbooks